(EuropeNewsWire.Net, May 16, 2018 ) Known more about Parkinson disease, symptoms and treatment Parkinsonís Treatment Market: Parkinson disease is a chronic, progressive neurodegenerative disorder that is characterized by tremors, rigidity, postural instability and bradykinesia (slow movement) with non-motor skills such sleep disturbances, in cognition, mood disturbance and autonomic dysfunction are also included. The disease is caused due to degeneration of the dopamine-producing cells of the substantia nigra. It is a slow-degenerative disorder which cannot be cured with poor life quality and increases disability.

Recent advances in the way of the treatment of Parkinsonís disease with combination or multiple medicines and therapies in order to prolong the action of the continuous stimulation of dopaminergic drugs, devices approval, etc. will help slow the degeneration of Parkinsonís diseases treatment globally. Factors such as an increase in older population, treatment affordability, an increase in the number of patients globally will help the market grow for Parkinson disease treatment. On the other hand, patent expiration, the rise in competitive drugs, and extensive unmet supply of the drug are some factors which can hamper the market growth of Parkinsonís disease treatment. The global Parkinsonís Treatment Market can be classified on the basis of drug class, treatment, end user, and geography.

2. End-usersHospital Pharmacies, online Pharmacies, and retail pharmaciesAnd lastly, it is divided on the basis of geographical regions-North America, Asia-Pacific, Europe, and the Middle East and Africa.

North America holds the first place in the global market for the Parkinsonís disease treatment due to a high incidence of the disease, and good reimbursement policies. According to the Parkinsonís disease Foundation, approximately 60,000 Americans are diagnosed with Parkinsonís disease every year. On the other hand, Europe holds the second place due to its share in the R &D investment and act as major players in the market. Some of the key players in the Parkinsonís treatment market are Salix Pharmaceuticals (US), GlaxoSmithKline (US), Wockhardt Limited (India), Impax Laboratories, Inc., (US), Cipla Inc. (India), Apotex Inc. (Canada), etc. are some names. In 2015 USFDA approved RYTARY, an extended-release oral capsule combination of Carbidopa and Levodopa of Impax Laboratories to treat Parkinsonís disease.

Parkinson disease is essentially treated with known and trusted medicines such as dopamine agonists and Levodopa, hence generic drugs still dominate the market. Newer technologies are making their way into the market to offer better quality treatment compared to conventional therapies. Drug manufacturers are accepting more options alongside the Levodopa therapy, therapy such as new product launches and collaborative agreements have been adopted so far. For e.g. Neuropore Therapies Inc. have collaborated with UCB S.A. for drug name NPT200-11, for the treatment of Parkinsonís disease.

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.